Pfizer Inc. buy BMO Capital Markets
Start price
16.10.23
/
50%
€31.50
Target price
16.10.24
€31.25
Performance (%)
-13.29%
End price
17.10.24
€27.32
Summary
This prediction ended on 17.10.24 with a price of €27.32. The prediction for Pfizer Inc. disappointed with a performance of -13.29%. BMO_Capital_Markets has a follow-up prediction for Pfizer Inc. where he still thinks Pfizer Inc. is a Buy. Dividends of €1.93 are taken into consideration when calculating the performance. BMO_Capital_Markets has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Pfizer Inc. | 3.534% | 3.534% | 3.975% |
| iShares Core DAX® | -1,09 % | 0,20 % | 2,09 % |
| iShares Nasdaq 100 | -2,46 % | -1,79 % | 29,25 % |
| iShares Nikkei 225® | -5,37 % | -5,43 % | 54,33 % |
| iShares S&P 500 | -0,20 % | 1,77 % | 23,58 % |
Comments by BMO_Capital_Markets for this prediction
In the thread Pfizer Inc. diskutieren
Pfizer Inc. (NYSE: PFE) had its price target lowered by analysts at BMO Capital Markets from $44.00 to $33.00. They now have an "outperform" rating on the stock.
Ratings data for PFE provided by MarketBeat
In the thread Trading Pfizer Inc.
Die von BMO_Capital_Markets gewählte maximale Laufzeit wurde überschritten